Biora TherapeuticsBIOR
About: Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.
Employees: 58
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5,433% more call options, than puts
Call options by funds: $166K | Put options by funds: $3K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 28 [Q1] → 29 (+1) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
10.23% less ownership
Funds ownership: 44.31% [Q1] → 34.08% (-10.23%) [Q2]
39% less capital invested
Capital invested by funds: $13.3M [Q1] → $8.07M (-$5.19M) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 90 / 259 met price target | 2,611%upside $15 | Buy Reiterated | 13 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 35% 1-year accuracy 90 / 259 met price target | 2,611%upside $15 | Buy Reiterated | 22 Jul 2024 |